Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Bevacizumab + Chemotherapy in 1L Cervical Cancer
NCT05444374Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in Cervical Cancer (CC), sponsored by Sichuan Cancer Hospital. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05444374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444374.